Trials / Active Not Recruiting
Active Not RecruitingNCT06476860
Proteinuria During Sepsis and Septic Shock: Characterization and Association With ARDS
Proteinuria During Sepsis and Septic Shock: Characterization and Association With Acute Respiratory Distress Syndrome
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Centre Hospitalier Intercommunal André Grégoire · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ARDS is a pulmonary edema injury. Among its etiologies, it can be secondary to septic shock. Managing septic shock involves hemodynamic optimization with significant fluid and sodium inputs. Fluid and sodium inputs in ARDS worsen respiratory failure through capillary leakage, and a restrictive input strategy is clinically beneficial (reduced mechanical ventilation duration and ICU stay). Predicting ARDS onset in septic shock allows for optimized fluid and sodium input management, adopting a restrictive rather than liberal approach to minimize deterioration in respiratory function.
Detailed description
Septic shock remains highly fatal, causing multi-organ failure including hemodynamic, pulmonary, neurological, renal, hematologic, and hepatic. These failures stem from generalized inflammatory aggression leading to endothelial dysfunction, especially at the capillary level. Pulmonary failure secondary to septic shock is characterized by edema, with ARDS being the most severe form. Sepsis is the second most common cause of ARDS after pneumonia. The incidence of ARDS in severe sepsis is about 6%, and its occurrence is an independent factor contributing to increased mortality. These failures significantly impact the management of septic shock, where early and often agressive, vascular filling is standard for hemodynamic failure. Conversely, the onset of ARDS onset warrants limiting hydro-sodium inputs. Currently, there are no data predicting the occurrence of ARDS patients with septic shock.
Conditions
Timeline
- Start date
- 2023-05-23
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
- First posted
- 2024-06-27
- Last updated
- 2024-06-27
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06476860. Inclusion in this directory is not an endorsement.